Who are nicotine patch plus nicotine gum/lozenge's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Motivation-Phase Nicotine Mini-Lozenge, Nicoderm C-Q Transdermal Product, Nicoderm Transdermal Patch, Nicoderm Patch, Nicorette Gum, C-11 labeled nicotine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-patch-plus-nicotine-gum-lozenge.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

nicotine patch plus nicotine gum/lozenge — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nicotine patch plus nicotine gum/lozenge (nicotine patch plus nicotine gum/lozenge) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT) combination. Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy (NRT) combination Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

nicotine patch plus nicotine gum/lozenge (nicotine patch plus nicotine gum/lozenge) — University of Minnesota. Nicotine patches and gum/lozenges deliver nicotine through different routes to bind nicotinic acetylcholine receptors in the brain, reducing withdrawal symptoms and cravings during smoking cessation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
nicotine patch plus nicotine gum/lozenge TARGET	nicotine patch plus nicotine gum/lozenge	University of Minnesota	marketed	Nicotine replacement therapy (NRT) combination	Nicotinic acetylcholine receptors
Motivation-Phase Nicotine Mini-Lozenge	Motivation-Phase Nicotine Mini-Lozenge	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Nicoderm C-Q Transdermal Product	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicoderm Transdermal Patch	Nicoderm Transdermal Patch	University of Pennsylvania	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
Nicoderm Patch	Nicoderm Patch	US Department of Veterans Affairs	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicorette Gum	Nicorette Gum	University of Miami	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
C-11 labeled nicotine	C-11 labeled nicotine	University of Cincinnati	marketed	PET imaging agent / radiotracer	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) combination class)

University of Minnesota · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nicotine patch plus nicotine gum/lozenge — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-patch-plus-nicotine-gum-lozenge. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab